Royalty and Commercial Payment Purchase Agreements - Viracta (Details) $ in Thousands |
6 Months Ended | |||
---|---|---|---|---|
Mar. 22, 2021
USD ($)
item
|
Jun. 30, 2023
USD ($)
|
Jun. 30, 2022
USD ($)
|
Dec. 31, 2022
USD ($)
|
|
Agreements | ||||
Payments of consideration under RPAs, AAAs and CPPAs | $ 14,650 | $ 5,000 | ||
Long-term royalty and commercial payment receivables | 72,232 | $ 63,683 | ||
Viracta | Royalty Purchase Agreement | ||||
Agreements | ||||
Number of drug candidates | item | 2 | |||
Payments of consideration under RPAs, AAAs and CPPAs | $ 13,500 | |||
Maximum amount of potential milestones and other payments receivable | 54,000 | |||
Amount of maximum consideration retained | 20,000 | |||
Maximum amount of potential regulatory and commercial milestones receivable | 57,000 | |||
Long-term royalty and commercial payment receivables | $ 13,500 | |||
Amount of allowance for credit losses | $ 0 | $ 0 |